Pathfinder Medical is a medical device company founded within Imperial College London in 2014.
Based in London, UK with in-house development and manufacturing facilities including an ISO Class 7 Cleanroom
The company is focused on developing its patented platform catheter guidance technology (ePATH) to advance endovascular procedures in peripheral interventions and vascular access creation
Sorin Popa is a visiting Researcher in the Department of Bioengineering at Imperial College London and an Enterprise Hub Fellow at the Royal Academy of Engineering. He has an Electrical Engineering degree with distinction from the University Western Ontario and a Research Masters degree with distinction in Medical Device Design and Entrepreneurship from Imperial College London. Sorin has research and development experience with implantable medical devices and was previously a co-founder of a social media marketing application.
Dan Brasier has over 15 years engineering experience within highly regulated industries with the last 8 years managing technical teams to commercialize medical devices. His most recent position was as Head of Operations Engineering for a leading UK developer of AAA SGs and delivery systems.
Daniel Kendal has more than 24 years of manufacturing engineering experience. He has successfully set up manufacturing operations in Asia and managed global supply chains. His most recent position was as a Senior Project Engineer for a leading UK developer of AAA stent grafts and delivery systems.
Richard Hall is an experienced QA professional with over 25 years’ experience of developing and manufacturing medical devices in a range of companies, from start-up to blue chip international healthcare businesses. He specialises in ISO 13485 quality management system or MDSAP certification and developing regulatory approval strategies.
The company has strong team of medical device professionals, including 3 PhDs and over 130 years of industry experience between them.
Alan Edwards has over 40 years experience in the healthcare industry both in the UK & US, having acted as a Chairman, Board member, Managing Director, Chief Executive & Executive Vice President of a number of companies. In 2001 he founded Credent Ltd, a vascular graft company, raising £10.5 million of Venture Capital to fund an MBO from CTI Inc. CTI was a NYSE public company co-founded by Alan who sold Credent in 2004 to a US company. Alan has specialised in developing and growing early stage medical technology companies.
Dr Haroon is Chairman and General Partner of Julz Co. He brings over two decades of development and business development in medical device and pharmaceutical industry. He has extensive transactional and M&A experience, both as direct lead and consultant, in venture and private equity held companies in health care industry. He has numerous board engagements and also maintains an appointment as Professor and Director at UNC Chapel Hill, NC.
Dr Savvas Neophytou is partner at Deepbridge Capital LLP where he heads up the firm’s Life Sciences business. He is a founding shareholder of a number of technology companies including Torafugu Tech which is engaged in personalised insurance underwriting. He has also been CEO of Now Healthcare Group, where he was part of the original team that set up Europe’s largest telemedicine platform Dr Now. Prior to that Savvas had a long career in the City, working for 15 years as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.
Mr Kayar Raghavan is a senior executive with rich international experience of 35 years in Banking business, operations and technology, Raghavan has also advised CEOs and performed due diligence for private equity deals. Currently a serial investor in, and advisor to, startups in the UK and India and he is a director on a few company boards as well as a charity. Raghavan is a FT-qualied Non-Executive Director who places great emphasis on Risk
This is independent research funded by the National Institute for Health Research (NIHR) under its Invention for Innovation (i4i) Programme (Grant Reference Number II-LA-0315-20006). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health further information can be found at www.nihr.ac.uk .